Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.75M$3.75Mderived+9.2% vs Q4 2024 Net Income-$776.00K-$776.00KderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,528,000+40.1% Operating Incomederived-$656,000N/M Operating Cash Flowderived-$95,000N/M Free Cash Flowderived-$142,000N/M Margins · derivedGross margin40.7%+9.0 pt vs Q4 2024
Operating margin-17.5%+23.5 pt vs Q4 2024
Net margin-20.7%+10.4 pt vs Q4 2024
ended Mar 31, 2025 · filed Jun 17, 2025 · 78 d after period end